EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Cost-effectiveness analysis of Atezolizumab plus bevacizumab vs. Rivoceranib plus Camrelizumab as first-line treatment for unresectable hepatocellular carcinoma

Mengmeng Liu, Tong Liu

Frontiers in Public Health · 05.06.2026 · 14

DOI: 10.3389/fpubh.2026.1749414 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Frontiers in Public Health, online erschienen am 05.06.2026. Verfasst von Mengmeng Liu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Harbin Medical University Cancer Hospital, Harbin, China. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Antibodies, Monoclonal, Humanized, Bevacizumab. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Harbin Medical University Cancer Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This study evaluated the cost-effectiveness of Atezolizumab plus Bevacizumab versus Rivoceranib plus Camrelizumab as first-line treatment of unresectable hepatocellular carcinoma (HCC) from the perspective of healthcare payers in China.

Methods

An economic evaluation using a 3-state partitioned survival model assessed the cost-effectiveness of Atezolizumab plus Bevacizumab versus Rivoceranib plus Camrelizumab. The Kaplan–Meier curves for overall survival (OS) and progression-free survival (PFS) from two clinical trials were digitally extracted, and the Weibull models were applied at the end of the trials to extrapolate long-term survival. The cost and health utility data were sourced from the published literature.

Results

The anticipated cost for Atezolizumab plus Bevacizumab exceeded that for Rivoceranib plus Camrelizumab (109,555.94 USD vs. 15,264.92 USD). The estimated utility for Atezolizumab plus Bevacizumab was decreased compared to that of Rivoceranib plus Camrelizumab (1.47 QALYs vs. 1.59 QALYs). The ICER was −742,858.34 USD/QALY, suggesting the Rivoceranib plus Camrelizumab treatment was cost-effective compared to Atezolizumab plus Bevacizumab as the first-line treatment for advanced or metastatic HCC patients.

Conclusion

Rivoceranib plus Camrelizumab was cost-effective compared to Atezolizumab plus Bevacizumab as a first-line treatment for advanced or metastatic HCC patients in China.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver NeoplasmsCarcinoma, HepatocellularAntibodies, Monoclonal, HumanizedBevacizumabPyridinesAntineoplastic Combined Chemotherapy ProtocolsQuinazolinesCost-Benefit AnalysisCost-Effectiveness AnalysisHumansChina

Stichwörter der Autor:innen

AtezolizumabBevacizumabCamrelizumabHCCRivoceranibcost-effectiveness

Substanzen

Antibodies, Monoclonal, HumanizedBevacizumabatezolizumabcamrelizumabPyridinesQuinazolines

Autor:innen und Institutionen

  • Department of Pharmacy, Harbin Medical University Cancer Hospital, Harbin, China.

Förderung

  • Harbin Medical University Cancer Hospital

Zitieren

APA

Liu, M., & Liu, T. (2026). Cost-effectiveness analysis of Atezolizumab plus bevacizumab vs. Rivoceranib plus Camrelizumab as first-line treatment for unresectable hepatocellular carcinoma. Frontiers in Public Health, 14. https://doi.org/10.3389/fpubh.2026.1749414

Vancouver

Liu M, Liu T. Cost-effectiveness analysis of Atezolizumab plus bevacizumab vs. Rivoceranib plus Camrelizumab as first-line treatment for unresectable hepatocellular carcinoma. Frontiers in Public Health. 2026;14. doi:10.3389/fpubh.2026.1749414

BibTeX
@article{Liu2026,
  author = {Liu, Mengmeng and Liu, Tong},
  title = {Cost-effectiveness analysis of Atezolizumab plus bevacizumab vs. Rivoceranib plus Camrelizumab as first-line treatment for unresectable hepatocellular carcinoma},
  journal = {Frontiers in Public Health},
  year = {2026},
  volume = {14},
  doi = {10.3389/fpubh.2026.1749414}
}
Kostenlos starten →